This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline ( Stiefel, a GSK Company ) Identifier:
First received: July 17, 2008
Last updated: September 23, 2011
Last verified: July 2008
This is a study of a new oral drug used for the treatment of psoriasis. All subjects will get active medication, there is no placebo arm.

Condition Intervention Phase
Psoriasis Drug: Talarozole Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Center Pilot Trial to Assess the Efficacy and Safety of Oral R115866 in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline ( Stiefel, a GSK Company ):

Primary Outcome Measures:
  • PASI Scores [ Time Frame: Various Visits ]

Enrollment: 19
Study Start Date: April 2004
Study Completion Date: December 2006
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Drug: Talarozole
1.0 mg oral dose per day
Other Names:
  • Rambazole
  • R115866


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female of non-childbearing potential (at least 2 years post-menopausal or undergone successful surgical sterilization at least 1 year before inclusion)
  • Presence of moderate to severe plaque psoriasis with a PASI of at least 5

Exclusion Criteria:

  • Pustular, guttate or other non-plaque forms of psoriasis or psoriatic arthritis
  • Significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic pancreatitis, osteoporosis, or a history indicating adrenal cortex dysfunction or any other serious disease (including cancer and subjects known to be HIV positive)
  • History of heart failure, myocardial infarction within the past six months, cardiac arrhythmia, or under treatment for heart disorders
  • Clinically significant abnormal ECG-intervals or morphology of the ECG; QT or QTc >470 ms in females or >450 ms in males
  • Use of vitamin A (>1000 µg/day), phenytoin, carbamazepine, warfarin, rifampicin, tetracyclines, ketoconazole, itraconazole, astemizole, terfenadine, cisapride, anti-psychotics, anti-depressants, lithium, antimalarials, alpha-blocking drugs, angiotensin-converting enzyme inhibitors, cyclosporin A, glucocorticosteroids and non-steroidal anti-inflammatory drugs, non-potassium-sparing diuretics
  • Previous use of any systemic immunomodulatory therapy (biologicals) or psoriasis vaccine
  • Use of other systemic therapy for psoriasis (e.g. PUVA, systemic steroids, cyclosporin A, methotrexate, retinoids) within four weeks prior to Visit 2
  • Use of UV therapy or excessive UV exposure or topical therapy for psoriasis other than bland emollients within two weeks prior to Visit 2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00725348

Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Universitair Medisch Centrum Nijmegen Sint Radboud
Nijmegen, Netherlands
Sponsors and Collaborators
Stiefel, a GSK Company
Principal Investigator: Prof. P. van de Kerkhof, MD, PhD University of Nijmegen, Maastricht, The Netherlands
  More Information

Responsible Party: Stiefel, a GSK Company Identifier: NCT00725348     History of Changes
Other Study ID Numbers: BT0700NED001
Study First Received: July 17, 2008
Last Updated: September 23, 2011

Keywords provided by GlaxoSmithKline ( Stiefel, a GSK Company ):

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
R 115866
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017